Use of pituitary adenylate cyclase-activating polypeptide (PACAP) and PACAP analogs for treating contrast-induced nephropathy

摘要

Featured are methods and compositions for treating, managing, preventing, or reducing injury to the kidney of a mammal (e.g., a human) caused by one or more iodinated radiocontrast media. The methods include administering an effective amount of one or more pituitary adenylate cyclase-activating polypeptide (PACAP)-like compounds, which includes native human PACAP38, native human PACAP27, native human vasoactive intestinal peptide (VIP), their agonists, analogs, fragments, and derivatives, with activities toward one or more of the PACAP/VIP receptors, including all of their various isoforms. Also provided are pharmaceutical compositions of one or more PACAP-like compounds, either alone or in combination with one or more other prophylactic/therapeutic agents useful for treating, managing, or preventing injury to the kidney of a mammal (e.g., a human) undergoing treatment with one or more iodinated radiocontrast media. Also featured is an in vivo mouse model for testing the efficacy of cytoprotective agents against contrast-induced nephropathy.

主权项

1. A method for treating, managing, preventing, or reducing an injury to a kidney of a mammal resulting from administration of an iodinated radiocontrast medium comprising administering to said mammal in need thereof an effective amount of at least one pituitary adenylate cyclase-activating polypeptide (PACAP)-like compound having at least 90% sequence identity to an amino acid sequence selected from any one of SEQ ID NOs: 1-76, wherein the PACAP-like compound treats, manages, prevents, or reduces said injuries to the kidney.